The UK's new car market experienced a 12.4% increase in March 2025, reaching 357,103 units, according to the Society of Motor ...

We recently published a list of 10 Firms Buck Thursday’s Market Bloodbath. In this article, we are going to take a look at ...

Truist Financial analyst Asthika Goonewardene maintained a Buy rating on Summit Therapeutics (SMMT – Research Report) today. The company’s ...

Truist Financial analyst Asthika Goonewardene maintained a Buy rating on Summit Therapeutics (SMMT – Research Report) today. The company’s ...

Fintel reports that on March 26, 2025, Citigroup upgraded their outlook for Summit Therapeutics (BMV:SMMT) from Neutral to Buy. Baker Bros. Advisors holds 24,425K shares representing 3.31% ...

According to the Society of Motor Manufacturers and Traders (SMMT), 51,221 vans, 4×4s, and pick-ups were registered.

Corebridge Financial Inc. decreased its holdings in Summit Therapeutics Inc. (NASDAQ:SMMT – Free Report) by 2.3% in the fourth quarter, according to its most recent filing with the Securities and ...

NASDAQ:SMMT opened at $20.60 on Wednesday. The stock has a market cap of $15.20 billion, a PE ratio of -73.57 and a beta of -1.04. The stock’s 50-day moving average is $20.49 and its two-hundred ...

Fintel reports that on March 26, 2025, Citigroup upgraded their outlook for Summit Therapeutics (NasdaqGM:SMMT) from Neutral to Buy. Analyst Price Forecast Suggests 71.90% Upside As of March 18 ...

The electric vehicle revolution continues to gain momentum with battery electric cars (BEVs) on UK roads surpassing one ...

We can readily understand why investors are attracted to unprofitable companies. Indeed, Summit Therapeutics (NASDAQ:SMMT) stock is up 347% in the last year, providing strong gains for shareholders.

Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 176,915 shares of common ...